Important to note Todos' Go to Market Strategy
Post# of 30067
(Total Views: 532)
Posted On: 06/05/2019 8:12:14 PM
Important to note
Todos' Go to Market Strategy for their Breast Cancer Screening Tests TM-B1 & TM-B2
They already got the go ahead to Market and sell within Israel with the Israeli Ministry Of Health.
They signed exclusive distribution and sales agreement with them.
Todos has already met with the FDA
FDA will accept Ex-US DATA
FDA also wants them to them to test in US.
They are working on finding the right US Lab partner.
Will be doing CLIA in parallel
That is important becase that allows them to sell the test based on accepted EX-US data.
Will launch initial pilot studies in 2 European countries Q3 2019
Austria & Romania.
Allows them to do things right and get things streamlined.
Once that is smooth then they will ramp up. Hockey stick growth.
So, owning roughly 50% of a company that is months away from selling, beginning trials and uplisting to the NASDAQ will change the direction of AMBS.
It will be the proof of concept of which Gerald has been working towards for Amarantus as a Holding Company.
Todos is well into the process and has some hurdles still, but well along their way.
With exciting things to come with their Blood Tests.
Colon Cancer & now Lung Cancer screenings in their cross-hairs.
(He mentioned EXAS...take a look at where they were in 2009....been in that one before that)
And as mentioned LymPro data going to be published
Looking to get a Pharma company to use and hopeful pharma company gets approved by the FDA which will then have LymPro as a companion diagnostic.
Not looking to make "general /generic claims such as 23 & Me just to sell a test.
He believes that would cause more panic and doing good.
That is only for Todos.
Todos' Go to Market Strategy for their Breast Cancer Screening Tests TM-B1 & TM-B2
They already got the go ahead to Market and sell within Israel with the Israeli Ministry Of Health.
They signed exclusive distribution and sales agreement with them.
Todos has already met with the FDA
FDA will accept Ex-US DATA
FDA also wants them to them to test in US.
They are working on finding the right US Lab partner.
Will be doing CLIA in parallel
That is important becase that allows them to sell the test based on accepted EX-US data.
Will launch initial pilot studies in 2 European countries Q3 2019
Austria & Romania.
Allows them to do things right and get things streamlined.
Once that is smooth then they will ramp up. Hockey stick growth.
So, owning roughly 50% of a company that is months away from selling, beginning trials and uplisting to the NASDAQ will change the direction of AMBS.
It will be the proof of concept of which Gerald has been working towards for Amarantus as a Holding Company.
Todos is well into the process and has some hurdles still, but well along their way.
With exciting things to come with their Blood Tests.
Colon Cancer & now Lung Cancer screenings in their cross-hairs.
(He mentioned EXAS...take a look at where they were in 2009....been in that one before that)
And as mentioned LymPro data going to be published
Looking to get a Pharma company to use and hopeful pharma company gets approved by the FDA which will then have LymPro as a companion diagnostic.
Not looking to make "general /generic claims such as 23 & Me just to sell a test.
He believes that would cause more panic and doing good.
That is only for Todos.
(4)
(0)